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Abstract 
Objectives: Methadone is the most commonly prescribed medication treatment in 
the United States for the treatment of opioid dependence.  Past research has found 
that people diagnosed with personality disorders require a higher level of 
methadone to satisfy their feelings of distress, emptiness and need to feel special. 
The researcher hypothesized that participants diagnosed with Borderline 
Personality Disorder would receive a higher level of methadone dose in 
milligrams than their other mentally disordered colleagues.  Methods: This study 
examines the influence of Borderline Personality Disorder, gender, age and Major 
Depressive Disorder has on the dosage levels of 184 clients who both receive 
methadone at a large metropolitan methadone clinic in the twin city area of 
Minnesota and have participated in mental health services offered by the same 
clinic.  Results:  Results of the research indicate lower methadone dosage levels in 
participants with BPD and methadone dosage levels compared to methadone 
dosage levels of other mental disordered participants.  Conclusion: The presence 
of BPD appears to be unrelated to methadone dosage levels. 
 
Keywords: Methadone, Borderline Personality Disorder, Major Depressive 
Disorder, opioid dependence 
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Introduction 
 
 Recent research has demonstrated that a high rate of patients in a 
methadone maintenance treatment (MMT) program met criteria for an Axis II 
diagnosis. Borderline Personality Disorder (BPD) is one of the highest reported 
Axis II diagnosis that MMT participants are diagnosed with by clinicians in a 
therapeutic environment (Darke, Williamson, & Teeson, 2005).  This study will 
attempt to find a relationship with the Axis II diagnosis of BPD with a higher 
prescribed dose of Methadone.  This will be compared to people with an Axis I 
Opiate Dependence Disorder (ODD) diagnosis that has a different Axis I or II 
diagnoses of mental illness as described in the DSM IV-TR, 2000 (American 
Psychological Association (APA, 2000). 
Opioid Dependence Disorder 
 
 Opiate Dependence Disorder on Agonist Therapy is as an Axis I disorder 
listed as 304.00 (APA, 2000).  This disorder is described in the Diagnostic and 
Statistical Manual of Mental Disorders Fourth Edition Text Revised (DSM IV-
TR) as individuals who: 
  Have significant levels of tolerance and will experience   
  withdrawal on abrupt discontinuation of opioid substances.   
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  Opioid Dependence includes signs and symptoms that   
  reflect compulsive, prolonged self-administration of opioid  
  substances that are used for no legitimate medical purpose   
  or, if a general medical condition is present that requires   
  opioid treatment, that are used in doses that are greatly in   
  an excess of the amount needed for pain relief.  Persons   
  with Opioid Dependence tend to develop such regular   
  patterns of compulsive drug use that daily activities are   
  typically planned around obtaining and administrating   
  opioids (APA, 2000 p. 270). 
 MMT is the primary way that people who are addicted to opiates seek 
relief from their dependence on opiates in the U.S.  MMT alleviates cravings for 
opiates such as heroin, morphine, Perkoset and Oxycodone and withdrawal 
symptoms such as profuse sweating, feelings of restlessness, sleepiness, stomach 
pains, body aches, anxiety, clumsiness and skin sensitivity in opiate addicts for up 
to twenty-four hours (Haertzen, Meketon, & Hooks, 1970).  MMT accomplishes 
this by acting as an agonist that mimics opiates by attaching to the receptors in the 
brain that opiates target when ingested (Lundgren, Schilling, & Peloquin, 2005).  
 MMT in the U.S. is a highly regulated treatment modality that requires 
both a prescription from a physician and regular counseling with a licensed 
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alcohol and drug counselor.   Initially MMT requires that a person receiving 
methadone show up to a licensed clinic daily to receive their prescribed dose of 
methadone from a licensed nurse.  Over time these meetings can become spread 
out to weekly visits to the clinic to receive take home doses of methadone and 
monthly visits with counselors but for the first ninety days a patient must show up 
to the clinic daily.  This process can be cumbersome and require a commitment to 
MMT that people who lack the time, transportation or childcare required to meet 
these rules may not be able to follow through with the program (Ross, Teeson, 
Darke, Lynskey, Ritter & Cooke, 2005). 
 Co-morbidity of a mental health disorder is high in people who are 
diagnosed with a substance abuse disorder (SUD).  It is also common to find 
cluster B personality disorders in people who have been diagnosed with a 
substance abuse disorder (Murray, McHugh, Behar, Pratt & Otto., 2008).  The 
Axis II diagnosis of BPD requires that a person exhibit some symptoms that are 
directly linked with substance abuse.  These include distress intolerance, drug 
seeking behaviors, impulsivity and anxiety.  These symptoms can be linked with 
the need for someone to seek a higher dose of methadone from a physician and is 
the foundation for this study (Murray et al., 2008). 
 It is important for physicians, nurses, alcohol, drug counselors and mental 
health therapists to be aware of the potential link between BPD and higher 
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methadone dose prescriptions so that these specific patients are not overprescribed 
and subsequently abuse methadone to treat or relieve their mental health related 
symptoms when they participate in an MMT. 
Literature Review 
 
 In 2003 there were over 180,000 admissions into treatment programs in 
the U.S. for opiate dependent injection drug users and this number has increased 
by 18% since 1992 (Corsi, Kwiatkowski, & Booth, 2007).  Injection drug use is 
the second largest exposure group for people diagnosed with Auto Immune 
Deficiency Syndrome (AIDS) in the U.S. (Corsi, et al., 2007).  Minimal research 
exists on the demographics of people participating in MMT.  In a study that 
examined the psychological differences presented among 900 African American 
and Caucasian users of MMT in the Philadelphia area some demographic data 
was identified (Platt, Steer, Ranieri, & Metzger, 1989).  This study found that 
74.2% of participants were male and 25.8% of patients were female.  The mean 
age of the participants was 31.77 years and the mean dose of methadone each 
participant received daily was 48.27 mg (Platt et al., 1989).  These demographic 
data points will be among some of the information explored in this examination of 
relationship between MMT, Axis I mental disorders and BPD in the twin city area 
of Minnesota.  
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 MMT is currently the most widely accepted form of treatment for opiate 
addiction in the U.S., England and Australia with the U.S. having the most 
federally regulated program of MMT (Ross, et al., 2005).  MMT is also 
considered the “gold standard” among treatment modalities related to opiate 
addiction because it treats the physical symptoms of withdrawal and the mental 
mindset of addiction (Reimer, Verthein, Karow, Schafer, Nabor & Haasen, 2011).  
Methadone is a synthetic form of opiate which provides relief from craving and 
withdrawal symptoms of people addicted to opiates.  The proper methadone dose 
can provide this relief for a 24 hour period.  This type of freedom from cravings 
and withdrawal gives the person in recovery the opportunity to obtain 
employment, housing and healthcare (Mistral & Hollingworth, 2001).  The 
alleviation of cravings and withdrawal symptoms also allows the MMT patient 
the opportunity to live a more stable life by removing the need to share needles, 
commit crimes to pay for drugs and enhancing the opportunity to care for 
dependent children (Lundgren et al., 2005).  MMT patients are less likely to 
remain homeless and have more stable relationships than opiate addicted 
homeless people who do not receive MMT (Royse et al., 2000). 
Borderline Personality Disorder 
 
 BPD is an Axis II diagnosis listed as 301.83 in the Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM IV-
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TR). The DSM IV-TR describes the behaviors of a person with BPD as having “A 
pervasive pattern of instability of personal relationships, self-image, affects, and 
marked impulsivity, beginning by early adulthood and present in a variety of 
contexts, as indicated by five (or more) of the following: 
  (1) Frantic efforts to avoid real or imagined abandonment. 
  (2) A pattern of unstable and intense interpersonal    
        relationships characterized by alternating between extremes of  
        idealization and devaluation. 
  (3)  Identity disturbance: markedly and persistently    
         unstable self-image or sense of self. 
  (4)  Impulsivity in at least two areas that are potentially   
         self-damaging (e.g., spending, sex, substance abuse,   
         reckless driving, binge eating). 
  (5)  Recurrent suicidal behavior, gestures, or threats, or   
         self-mutilating behavior. 
  (6) Affective instability due to a marked reactivity of mood                        
         (e.g., intense episodic dysphoria, irritability, or anxiety  
           usually lasting a few hours and only rarely more than   
           few days) 
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  (7) Chronic feelings of emptiness 
  (8) Inappropriate, intense anger or difficulty controlling   
        anger (e.g.,  frequent displays of temper, constant   
        anger, recurrent physical fights) 
  (9) Transient, stress-related paranoid ideation or severe   
        dissociative symptoms (APA, 2000, p.710) 
 Co-morbidity with a Substance Use Disorder (SUD) and a lifetime mental 
illness is estimated to be 51% by the National Comorbidity Survey (2007.  This 
makes screening for mental illness in people with SUD an important part of 
substance abuse counseling (Brooks, Malfait, Brooke, Gallagher, & Penn, 2007).  
 Substance Use Disorder includes both Substance Dependence Disorder 
and Substance Abuse Disorder. These disorders fall under the umbrella of 
Substance Related Disorders and do not include Substance Induced Disorders 
(APA, 2000). Criteria for Substance Dependence Disorder include: 
 A maladaptive pattern of substance use, leading to 
 clinically significant impairment or distress, as manifested 
 by three (or more) of the following, occurring at any time 
 in the same 12-month period: 
(1) Tolerance 
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(2) Withdrawal 
(3) The substance is often taken in larger amounts or over a longer 
period than was intended 
(4) There is a persistent desire or unsuccessful efforts to cut down 
or control substance use 
(5) A great deal of time is spent in activities necessary to obtain 
the substance, use the substance or recover from its effects 
(6) Important social, occupational, or recreational activities are 
given up or reduced because of substance use 
(7) The substance use is continued despite knowledge of having a 
persistent or recurrent physical or psychological problem that is 
likely to have been caused or exacerbated by the substance (p. 
197) 
Substance Abuse Disorder 
 
 Substance Abuse Disorder (SAD) has a different set of criteria than SUD 
and is meant to be a more serious disorder.  Criteria for meeting a diagnosis of 
SAD include: 
A. A maladaptive pattern of substance use leading to clinically 
significant impairment or distress, as manifested by one (or 
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more) of the following, occurring within a twelve month 
period: 
(1) Recurrent substance use resulting in a failure to fulfill major 
role obligations at work, school, or home 
(2) Recurrent substance use in situations in which it is physically 
hazardous 
(3) Recurrent substance–related legal problems 
(4) Continued substance use despite having persistent or recurrent 
social or interpersonal problems caused or exacerbated by the 
effects of the substance 
B. The symptoms have never met the criteria for Substance 
Dependence for this class of substance (APA, 2000, p. 199) 
 The rate of MMT patients with BPD is alarmingly high.  While the 
prevalence of BPD in the general population is estimated to be 2%, as many as 
65% of MMT patients diagnosed with an Axis I diagnosis of SUD exhibit the 
criteria that merits an Axis II diagnosis of BPD (Darke, et al., 2007).  This is 
attributed to the common opiate addicted behaviors and feelings that are included 
in the SUD diagnosis.  These include feelings of impulsivity, emptiness, identity 
disturbance, lack of anger control, intense and frequent mood changes and self-
injurious behavior (Darke et al., 2007). These symptoms should be alleviated by 
the use of methadone given in a proper dosage level.  It is important to determine 
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if the rates of BPD prevalence occur in the Twin City metropolitan clinic where 
this current research took place so that dosing policy may be more informed 
locally. 
 The singular predictor of having BPD is that of having poly-substance use.  
In their study of poly-substance users Darke, Torok, McKetin, Kaye and  Ross. 
(2011) found that the acquisition of BPD was strongly correlated to elevated 
levels of poly drug use and at a younger age. Also found that heroin users 
exhibited elevated signs of depression, hostility and paranoia (Darke et al., 2011).  
This finding is concurred by Darke and colleagues when they performed a 36 
month study of heroin addicts in Australia they found an increase of BPD 
symptoms in a longitudinal study that lasted 36 months and gave researchers time 
to make an accurate diagnosis of BPD.  The symptoms that Darke and colleagues 
found included higher rates of suicide attempts, overdose, needle sharing among 
users and a diagnosis of major depression (Darke, Ross, Williamson, Mills, 
Havard, & Teeson., 2007).  Darke and colleagues’ research implies that heroin 
use is associated with a variety of mental health diagnoses and should be 
considered when completing a mental health diagnostic assessment with patients.  
Ross et al. (2005) also reported a higher level of risk-taking behaviors in people 
who were diagnosed with both SUD and BPD.  These behaviors include chronic 
suicide attempts, recent suicide attempts, lifetime overdose, poly-substance abuse, 
depression and needle sharing.  These elevated acts of harm led Ross (2005) to  
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advise that all heroin users entering treatment should be screened for BPD (Ross 
et al., 2005).   
 These symptoms are highlighted in Feske, Tarter, Kirisci and Pilkonis’s 
(2006) study of 232 women with BPD and SUD. In their study of women with 
both a SUD and BPD diagnosis, they found that women were at a greater risk of 
participating in such severe activities that put their lives at risk.  These activities 
included participation in the sex trade, higher number of sexual partners, more 
frequent and severe drug overdoses, needle sharing, higher rates of suicide 
attempts and poorer responses to treatment for their chemical addictions (Feske, et 
al., 2006).  Darke et al. (2005) reported that an estimated 8 to 10 percent of people 
diagnosed with BPD commit suicide (Darke et al, 2005).  These factors make 
screening for BPD in women with a SUD diagnosis an important part of the 
assessment process. 
 The use of Methadone in treating opiate addictions is not an exact science.  
Doctors who prescribe methadone dosage amounts rely heavily on the clients’ 
self-report of symptomology to determine what dose is the proper one for 
someone seeking relief from opiate withdrawal and cravings (Murray et al., 
2008).  A person who is diagnosed with ODD and BPD is likely to have lower 
stress tolerance and report more physical distress and psychological cravings to a 
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physician in charge of determining what should be their proper dose (Murray et 
al., 2008).   
 The use of blood tests to determine whether a client is being under-
prescribed or over-prescribed methadone is a relatively new process in the MMT 
field. One article related to anxiety and methadone dosage levels in MMT 
participants in Israel indicates that that patients who receive a dose above 100 
milligram are more likely to abstain from opiate use thus they test for methadone 
efficacy at or above 100 milligrams (Sciff, Levit, Schori, & Lowental, 2011). 
 Multiple stigmas exist when it comes to seeking help with a SUD and 
BPD diagnosis.  Despite its popularity as a treatment modality for opiate 
addiction, MMT is still perceived by the public as a negative treatment process for 
people who have been addicted to opiates.  Combined with the stigma related to 
mental illness, it is hard for those who have a co-morbid diagnosis of SUD and 
BPD to seek treatment for their illness (Connor & Rosen, 2008).  These barriers 
have been identified as major factors in a person with ODD who is diagnosed 
with BPD from seeing a mental health worker on a regular basis (Mistral & 
Hollingworth, 2001). 
 In a 12 month study of heroin users with a BPD diagnosis and those 
without BPD, Darke, et al. (2005) found that while seeking treatment those 
participants who were diagnosed with BPD experienced a decline in drug use 
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similar to those without BPD yet those participants with BPD still engaged in a 
higher level of risk taking behaviors than participants with a SUD diagnosis but 
no BPD diagnosis (Darke, et al., 2005). 
 Thus it is important to the social work field to determine whether clients 
who receive both mental health counseling services combined with MMT are 
receiving a therapeutic dose of methadone and not being overprescribed a dosing 
level because of elevated self-reported distress levels.  This research study will 
attempt to ascertain whether clients who are diagnosed with BPD do in fact 
receive a higher dose of methadone in comparison with other clients who receive 
mental health counseling and participate in MMT. 
Theoretical Framework 
 
The theory that informs this study is the idea that specific behaviors 
including distress intolerance, drug seeking behaviors and feelings of emptiness in 
a person diagnosed with BPD will affect the dosage level of methadone that a 
person participating in MMT will receive from the prescribing physician (Murray 
et al., 2008). 
 Clinicians and physicians in an MMT program rely heavily on the self-
report of the effect of methadone in the reduction of cravings and withdrawal 
symptoms. In this study patients were observed by a nurse at time of dosing and 
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required to have blood work performed to assess for the efficacy of the patients 
current dose before a higher dose was prescribed. There is very little in the way of 
consistency when it comes to determining what dosage amount should be 
considered the baseline determining when testing should occur for participants in 
an MMT program. This inconsistency is seen in the process that MMT programs 
in Israel, where a dosage amount of 100 milligrams is considered a baseline for 
efficacy (Schiff et al., 2011) or Australia where any dose over 120 mg is 
considered a high dose (Bryne, 1999).  In this study any dosage level above 150 
mg will be considered a high dosage level and patients may be denied the higher 
dose if their blood work shows that their current dose is medically effective. 
 People diagnosed with BPD have demonstrated a higher amount of 
distress intolerance, a history of drug seeking behavior, impulsivity and sensation 
seeking behavior (Murray et al., 2008).  These symptoms can combine to promote 
distress intolerance which causes a person in MMT with BPD to ask for a higher 
dose of methadone to relieve the distress they are feeling whether it is real or 
imagined.   
Methods 
 
 The data used for this study was procured by the author from clients’ 
medical files and mental health case notes.  Permission to use this data was given 
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by the client when they were completing the intake process at the clinic.  Client 
files and notes were examined solely for data to be used in this study.  Clients’ 
age, gender and methadone dosing levels were recorded from their medical files 
while the clients’ mental illness diagnosis was gleaned from their mental 
diagnostic assessment.  This information was transcribed to a measurement 
instrument which recorded the clients’ age, gender, methadone dose and mental 
illness diagnosis. 
 All participants in this study received a mental health diagnostic 
assessment between January of 2010 and February of 2013 by a licensed 
independent clinical social worker or by one of six clinicians under their 
supervision.  These clinicians included Licensed Marital and Family Therapists 
(LMFT) and interns in in the LMFT and Masters Social Work (MSW) fields.  No 
client who had been diagnosed with a mental illness by the researcher was 
included in this study.  Each participant in this study was receiving methadone 
from a licensed clinic in an urban city in the Twin Cities area of St. Paul and 
Minneapolis, Minnesota and had received at a minimum a diagnostic mental 
health screening in a separate part of the same clinic. 
 All patients at the clinic are tested for methadone efficacy before they can 
receive a dose higher than 150 milligrams.  This standard of blood testing is a 
relatively recent change to MMT that is not reflected in the literature. It is 
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important to note that each clinic has a different standard for testing patients for 
methadone efficacy. This effort to ensure a therapeutic dosing level is achieved 
removes the opportunity for someone to receive a dose higher than 150 
milligrams without proving that they are metabolizing the methadone at a higher 
rate than most patients.  This does not preclude incidents of higher reports of 
distress by participants and them achieving a higher dosing level but it does cap 
the amount of methadone they receive at 150.  They subjected to testing to ensure 
that their dose was not at a therapeutic level before it is increased. 
Study Purpose and Design 
 
 The location of the data for the participants in this study is situated in a 
large urban methadone clinic in Minnesota. This is a quantitative study.  The data 
used in this secondary analysis of methadone patients was procured with written 
agency approval.  Patient files were examined by the author for age, gender, 
diagnostic assignment of mental disorders and dosage level of methadone in 
milligrams for each participant and recorded on a separate data collection form 
(Appendix A). 
 The purpose of this study is to determine if having an Axis II diagnosis of 
Borderline Personality Disorder has a relationship with a higher methadone dose 
level than that of patients with other Axis I and Axis II diagnoses.  Other variables 
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to examined include age, gender, current methadone dose levels and Axis I or 
Axis II  DSM – IV TR diagnoses. The data that was collected will be subjected to 
analysis by SPSS 19.  SPSS 19 is a statistical analytic computer program that will 
process the data and give descriptive information such as mean age, mean 
methadone dose, number of male and female participants as well as provide 
information as to what the mean methadone dose for the most common co-morbid 
diagnoses that were identified. 
 The question this study will attempt to answer is:  Do participants in an 
urban MMT program with an Axis II diagnosis of BPD receive a higher 
methadone dose level than other clients who have a different mental illness 
diagnosis?  The hypothesis for this study is that participants diagnosed with BPD 
will have received a higher daily methadone dose than other mentally ill clients.  
The null hypothesis is that study participants with an Axis II diagnosis of BPD do 
not receive a higher daily methadone dose than participants without a diagnosis of 
BPD. 
Measures for Protection of Human Subjects 
 
 No one but the author of this study played an active role in the 
examination of patient files selected for this study.  Patients were selected for the 
study if they participated in the mental health program at the clinic and had been 
given an Axis I and/or Axis II diagnosis between January of 2010 and February of 
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2013. No patient records were printed or recorded with their name affixed.  All 
data collected was that of patients over the age of eighteen and active participants 
in a methadone maintenance program and had received a mental health diagnosis. 
Each patient must have been given a co-morbid diagnosis by a Licensed 
Independent Clinical Social Worker (LICSW) or one of six clinicians under their 
purview.  Each patient in the study also had given permission to have their data 
used for research purposes as part of their intake into the MMT program. This 
written permission document can be found in Appendix B. Approval for this 
study was grant by the Institutional Review Board of St. Catherine’s University. 
Assumptions and Limitations 
 
 This study was conducted at a methadone clinic which offers mental 
health services to participants who desire them. It is assumed that all diagnoses 
were correctly assigned to each client in the study.  It is assumed that each patient 
entering or participating in MMT has a SUD or SAD diagnosis.  Also assumed is 
that each methadone dose given to a participant in this study was a therapeutic 
dose and thus the participant was not given too high or too low a dose for their 
particular medical needs.   It is also assumed that patients in the MMT and mental 
health therapy programs at the clinic represent similar MMT patients who have 
been diagnosed with a mental disorder as described in the DSM IV-TR. 
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 Limitations to this study include the fact that all patients at the methadone 
clinic have not received a mental illness diagnosis thus, the study excludes clients 
who may have an undisclosed diagnosis. In addition, no methadone patients 
without a mental illness participated in this study.  This implies that there are 
participants in MMT at the clinic that have a legitimate mental illness but either 
has gone undiagnosed or the participants seek therapeutic services from therapists 
outside of the clinic that is in this study.  The number of patients diagnosed with 
BPD in this study was smaller than the literature review has indicated the norm 
for mentally ill clients who participate in MMT. Only seven patients in this study 
were diagnosed with BPD. This could be due to the length of time patients’ 
symptoms have to be presented to the therapist before a diagnosis of BPD is 
assigned to the patient. No rule outs of BPD in the diagnostic assessments were 
considered in this study. This may have played a role in the number of patients 
who were identified as having BPD.   
 The behaviors of patients with a diagnosis of BPD can be disruptive in the 
clinic and in the therapeutic setting.  These behaviors could affect the way 
physicians and nurses treat patients with BPD.  A patient whose feelings and 
actions related to distress can cause a physician or nurse to treat this client 
differently.  Blaming the symptoms of BPD for feelings of distress, physical 
anxiety and requests for a higher dose will cause a physician or nurse to refuse to 
raise a dosage level in patients diagnosed with BPD. 
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  No methadone patients without a mental illness diagnosis participated in 
this study.  This implies that there are participants in MMT at the clinic that have 
a legitimate mental illness but either has gone undiagnosed or the participants 
seek therapeutic services from therapists outside of the clinic that is in the study. 
 
Findings 
 
 The researcher examined and recorded client data from the clinical case 
files of 184 patients who were participants in both the MMT and mental health 
clinic services of an urban methadone clinic in Minnesota.  All participants had 
received a mental illness diagnosis as described in the Diagnostic and Statistical 
Manual Text Revised 4th edition by an LICSW or a mental health professional 
under their purview and were participating in the MMT program. Participants’ 
age, gender and dosage level was found in a computer program entitled 
Methasoft.  Participants mental illness diagnosis was found in an on-line software 
program entitled Procentive.  Each participant’s age, gender, mental illness 
diagnosis and methadone dosage level were entered on a data instrument that is 
found in Appendix A and then transcribed into a statistical analysis program 
entitled SPSS 19.  This program analyzed the data and gave the researcher both 
descriptive statistics which were then placed into tables for easier dissemination. 
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Descriptive Statistics 
 
 The first descriptive statistic that was examined was gender. Of the 184 
participants in the study 104 were female and 80 were male.  This finding 
demonstrates that 56 percent of the study sample is female and 44 percent of the 
study sample was male.  The mean age of participants in this study was found to 
be 34 years of age.  The age range for participants in this study is 50 years, with a 
minimum age of 19 years and a maximum age of 69 years.  These are all found in 
Table 1. 
 Dosage Variable is the ratio level variable was operationally defined as the 
current methadone dose in milligrams that a participant was receiving at the time 
the data was collected.  The minimum dose that a participant received was 5 
milligrams and the maximum dose a participant received was 320 milligrams.  
The mean dose in milligrams for all participants is 121.7446 milligrams with a 
standard deviation of 48.30442 milligrams 
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Table 1.  
Description of the Sample 
 n % 
Gender 
         Male 
         Female 
 
80 
104 
 
43.5 
 
56.5 
 
Age 
      18-20 
      21-30                                                  
      31-40 
      41-50 
      51-60 
      61-70 
 
5 
 
80                                          
 
44 
 
36 
 
14 
 
5 
 
 
2.7 
 
43.5 
 
23.9 
 
19.6 
 
7.6 
 
2.7 
 
Results 
 
  The second variable was methadone dosage level per day in milligrams. It 
was operationalized by recording the amount of methadone the client received per 
day at the time of this study and transcribed from the data instrument used in this 
study.   A Levene’s Test for equality of Variances shows that the mean 
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methadone dose level for females was 121.3750.  The mean methadone dose for 
males was 122.2250 milligrams. When compared to each other in a single tailed 
T-Test they produce a p value of .906 which is greater than .05 thus indicating 
that gender does not play a statistically significant role in methadone dosing levels 
received from clients at the clinic. 
 As seen in Table 2, seven participants in the study were diagnosed with 
Borderline Personality Disorder.  The Levene’s Test for Equality of Variance 
stated that the mean dosage level of methadone for these seven participants was 
120.7143 milligrams and the mean dose of methadone for the other 177 
participants was 121.7853 milligrams. When the means were compared to one 
another they produced a p value of .954 which is greater than .05 thus indicating 
that Borderline Personality Disorder does not play a statistically significant role in 
the amount of methadone a client receives from the clinic. This finding caused the 
researcher to fail to reject the null hypothesis.  Borderline Personality Disorder 
does not play a role in the amount of methadone a client received. 
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Table 2.  
Dosage levels by diagnosis 
Diagnosis n Dosage (µ)           % 
 
*BPD 
 
7 
 
120.7143 
 
3.8   
 
MDD 92 126.5326 50.0 
 
GAD            33 132.1627 
 
17.9 
 
PTSD 
 
Adjustment 
Disorder  
 
Dysthymic 
Disorder   
 
Bipolar I 
 
ADHD     
 
OCD   
 
Panic with and 
w/o 
Agoraphobia  
 
Drug Induced 
Mood Disorder                         
12 
 
26 
 
 
8 
 
 
6 
 
4 
 
1 
 
 
 
1 
 
1 
121.8125 
 
113.2608 
 
 
138.7500 
 
 
123.8888 
 
107.5000 
 
150.0000 
 
 
 
190.0000 
 
200.0000 
6.5 
 
14.1 
 
 
4.3 
 
 
3.3 
 
2.2 
 
.5 
 
 
 
.5 
 
.5 
 
*Axis II diagnosis         
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 The next comparison that was made was the diagnosis of Major 
Depressive Disorder (MDD) and all other disorders. The first variable that was 
operationalized was (MDD).  MDD is a nominal variable.  It was operationalized 
from the data recording instrument as MDD mild, moderate or severe. A 
participant either had been diagnosed with some level of MDD or they had not 
been diagnosed with some level of MDD.  The second variable that was 
operationalized was methadone dosage level.  Methadone dosage level is a ratio 
level variable that was operationalize by recording the amount of methadone in 
milligrams that a participant received daily from the clinic.  
 The next research question for this study is: Do methadone dosage levels 
in participants with MDD differ from those not diagnosed with MDD?  The 
hypothesis for this question is that participants with MDD will have received a 
different dose of methadone than those who were not diagnosed with MDD.  The 
null hypothesis for this question is that participants in this study that have MDD 
diagnosis will not receive a different methadone dose level in milligrams than 
those participants without an MDD diagnosis. 
 The study found that ninety-two participants were diagnosed with some 
level of Major Depressive Disorder and ninety-two participants were not 
diagnosed with MDD.  The mean level of methadone given to those diagnosed 
with MDD was 126.5326 milligrams with a standard deviation of 54.26177 
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milligrams and those with no MDD received 116.9565 milligrams with a standard 
deviation of 41.25022 milligrams.  The mean level of methadone dose given to 
those with a diagnosis of MDD was ten milligrams higher than those with a 
diagnosis of MDD. 
 The results of an independent samples shows T-test of the mean levels of 
methadone each participant received daily found that there was a difference in the 
amount of methadone a participant received depending on whether or not their 
diagnosis was MDD.  The Levene’s test of equality of variance is .005.  This is 
significant because it is less than .05.  Therefore the p-value for this t-test is .180 
which indicates there is no statistical difference between methadone dose levels of 
participants diagnosed with MDD and those participants not diagnosed with 
MDD.  As a result we must fail to reject the null hypothesis that participants in 
this study that have a MDD diagnosis will not receive a different methadone dose 
level in milligrams than those participants without an MDD diagnosis. 
 The next variable that was analyzed was the client’s age.  The second 
variable that was used was methadone dose levels.  This was operationalized as 
was previously explained.   
 The next research question that was examined through use of this 
correlation was: What is the relationship between age and methadone dose levels?  
The hypothesis for this question is that there will be a relationship between age 
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and methadone dose levels of participants.  The null hypothesis is that there will 
not be a relationship between age and methadone dosage levels.  
 The researcher found the mean methadone dose levels for all participants 
in the study, and the mean age of participants in the study.  The mean methadone 
dose level was 121 milligrams and the mean age was 34 years.  The calculated 
correlation (r= .251, p <.05) indicating a weak and positive correlation.  This 
indicates that when age increases methadone dose levels increases slightly. This is 
a weak correlation because the participants’ responses are not consistent with a 
line of best fit. 
 The last variables that should be considered are patient’s identified mean 
methadone dose and their diagnoses of Dysthymic Disorder, Generalized Anxiety 
Disorder, Posttraumatic Stress Disorder and Adjustment Disorder as well as 
mental disorders that were identified in the study but did have enough respondents 
to be considered significant. 
 Dysthymic Disorder is a disorder that is identified in the DSM IV-TR as 
chronically depressed mood for most of day for more days than not for at least 
two years.  (APA, 2000 p.376).  The eight patients with a diagnosis of Dysthymic 
Disorder reported the largest mean of all diagnosis with at least four participants.  
These patients reported a mean of more than 138 milligrams.  This elevated mean 
may indicate that patients report feelings of withdrawal related to depression over 
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a longer period of time to physicians and nurses thus elevating the dosage level to 
a point still under the 150 milligram threshold but still the highest in this study. 
 Generalized Anxiety Disorder (GAD) is a disorder that is identified in the 
DSM IV-TR as having the essential feature of, “excessive anxiety and worry, 
occurring more days than not for a period of at least six months, about a number 
of events or activities.  The individual finds it difficult to control the worry (APA, 
2000 p.472).  Thirty-three patients in the study had received a diagnosis of GAD.  
This was the second most identified diagnosis in the study after MDD.  
 Patients with a diagnosis of GAD reported a mean methadone dosage level 
of over 132 milligrams.  This elevated level of methadone dose could be related to 
the patients’ report of worry that the dose was not holding them the full twenty-
four hours, anxiety related to symptoms of withdrawal or the increased 
metabolism associated with excessive anxiety and worry. 
 Posttraumatic Stress Disorder (PTSD) is a disorder that is identified in the 
DSM IV-TR as having the development of characteristic symptoms following 
exposure to an extreme traumatic stressor that involves actual or threatened death, 
serious injury or threat to the physical integrity of a person or the witnessing of a 
life taking or threatening event to another( APA, 2000 p.463).  PTSD was 
identified in twelve of the studies participants.  Participants diagnosed with PTSD 
reported a mean methadone dosage level of 121 milligrams.  This amount of 
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methadone dose is the same as the mean for all the participants in the study.  This 
indicates that PTSD symptoms play no significant role in the amount of 
methadone they received daily in comparison with other participants in this study. 
 The lowest reported mean dose for all diagnosis with more than four 
identified participants belongs to patients diagnosed with Adjustment Disorder 
with Mixed Anxiety and Depressed Mood.  Adjustment Disorders are associated 
in the DSM IV-TR as, “a psychological response to an identifiable stressor or 
stressors that results in the development clinically significant emotional or 
behavioral symptoms”(APA, 2000 p.679).  The reported mean dosage level of the 
twenty-six participants with an Adjustment Disorder with Mixed Anxiety and 
Depressed Mood was 113 milligrams.  This mean dosage level is a full eight 
milligrams lower than the mean of all participants indicating that participants with 
Adjustment Disorder with Mixed Anxiety and Depressed Mood experience 
symptoms that are transitory in nature and do not require a patient to seek more 
methadone to alleviate these symptoms. 
 The lowest mean dose reported for a diagnosis was patients diagnosed 
with Attention Deficit/Hyperactivity Disorder (ADHD).  Four patients with 
ADHD reported a mean methadone dosage level of 107 milligrams.   
 Other mental illness diagnosis and methadone dosage levels identified in 
the study were Bipolar I (6 participants) 123 milligrams, Drug Induced Mood 
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Disorder (1 participant) 200 milligrams, Obsessive Compulsive Disorder (1 
participant) 150 milligrams and Panic Disorder With and Without Agoraphobia (1 
participant) 190 milligrams 
Discussion 
 
 The failure to reject the null hypothesis that methadone dosage levels do 
not increase in clients diagnosed with BPD is not consistent with previous studies.  
This may be due to increased knowledge in the medical field about how 
methadone is metabolized in each person regardless of the physical or emotional 
distress they report to the physicians and nursing staff at the clinic that 
participated in this study.  The participants in this study were tested for 
methadone metabolization after reaching a level of 150 milligrams. This is a 
threshold that is determined by physicians who supervise the administration of 
methadone to patients.  Different physicians have different ideas about at what 
level of methadone the client receives before he/she should be tested for the 
efficacy of the methadone.  The threshold at the clinic in this study was 150 
milligrams. This manner of testing may play a role in negating the influence of 
self-report in clients as they seek a higher methadone dose to alleviate distress. 
 The mean methadone dose for all participants in the study was 121 
milligrams. This level of dosage is consistent with the dosage level of participants 
who were not diagnosed with BPD who also report a mean dosage level of 121 
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milligrams.  Those participants diagnosed with BPD reported a mean dosage level 
that was one milligram lower at 120 milligrams.  This lower mean dose of 
methadone among participants with BPD in comparison with the other mentally 
disordered participants in this study is substantially below the level of 150 
milligrams at which they would be tested for dose efficacy.  This data suggests 
that the physicians and nursing staff at the clinic are properly operating the 
methadone delivery system to its patients. 
 When gender was considered as a variable, a weak correlation (r=.009) 
was identified between males and females and their respective mean methadone 
dosage levels.  Men in fact received only one (121) milligrams more as a 
population than women (120) milligrams.  This is significant in that it 
demonstrates that the clinic does not give higher doses to men or women based on 
their gender. It also may indicate that men metabolize at a faster rate than their 
female counterparts in this study. 
 The mean age of the participants in this study was 34 years of age.  This is 
consistent with previous research that has identified the mean age of participants 
in a MMT program in Philadelphia to be almost 31 years of age (Platt, et al., 
1989).  What the findings in this study did reveal related to age was a weak 
correlation between age of participant and a higher methadone dosage level.   
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 In this study methadone dosage levels increased as participants grew 
older.   This was identified as a positive yet weak correlation (r = .251) between 
advancing age and higher methadone dosing levels. This correlation could be 
related to tolerance level increasing with age though time spent in MMT was not 
measured.  The ambiguity of these results could be seen as a reason for more 
research into what causes increased dosage levels of methadone. 
 In this study the most reported mental illness diagnosis among the 184 
participants was MDD.  MDD and its three subtypes (mild, moderate and severe) 
accounted for 50% of study participants.  Study participants with a diagnosis of 
MDD demonstrated a mean methadone dose level of 116 milligrams.  Study 
participants who were diagnosed with MDD had a mean methadone dosage level 
of over 126 milligrams.  This data states that there is a relationship with MDD and 
a higher methadone dosage level.  The number of participants diagnosed with 
MDD is worth discussing because of its high level of report at this clinic. When 
fifty percent (50%) or more of participants in a study are given the same diagnosis 
it may be worth future investigation as to how the diagnostic process is followed 
at the clinic.  Also worth future investigation may be the fact that the mean dosage 
level for patients diagnosed with Generalized Anxiety Disorder was found to be 
over 132 milligrams in 33 of the participants in this study. 
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Conclusion 
 
 The method used to define a therapeutic methadone dose in patients poses 
a challenge to how providers think about dosing levels.  No longer are the nurses 
and the physicians solely responsible for raising and lowering a dosage level 
based solely on patient self-report. The patients at the large urban methadone 
clinic in which this study was conducted were tested for dose efficacy by means 
of a simple blood test when they dose they requested was above 150 milligrams. 
This test, which measures the length of time that methadone is at a therapeutic 
level in the bloodstream, ensures that patient report of distress, history of drug 
seeking behavior and intolerance of withdrawal are addressed when the patient’s 
dose reaches 150 milligrams or they show signs of overdose such as drowsiness. 
 The mean methadone dose level of all mental health clients in this study 
was identified as 121 milligrams.  When the mean methadone dose levels of all 
patients were compared by age, gender and MDD the only significant 
relationships with a higher dose of methadone were age and presence of MDD. 
   When age is correlated with methadone levels it shows a slight rise in 
dosage levels as patients get older. This correlation is not a strong one but is 
notable due to the fact that it was an identifiable correlation to a higher dose of 
methadone (r=.251).  This correlation of older participants receiving a higher dose 
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of methadone is worthy of future study to determine if it remains a correlation 
when the population of patients at the clinic as a whole is surveyed. 
 MDD was the highest reported mental disorder in participants in this 
study.  Participants with a diagnosis of MDD reported a mean dose of 126 
milligrams.  While other diagnoses were not examined it is important to note that 
participants with a reported a mean dosage level of methadone that was nearly10 
milligrams higher than the mean dose for participants that did not have a 
diagnosis of MDD and 5 milligrams higher than the overall mean dose for all 
participants. 
Implications for Social Work 
 
 Previous research and studies have found that people diagnosed with BPD 
and participated in MMT have received a higher dosage level of methadone than 
that of patients with a different diagnosis.  This study of 184 patients in a large 
urban methadone clinic in Minnesota has found that it is not necessarily so 
anymore. The seven patients who were diagnosed with BPD showed a milligram 
lower level of methadone than those patients who were diagnosed with something 
other than BPD.  This fact caused the researcher to fail to reject the null 
hypothesis of this study and acknowledge that the factors associated with a 
diagnosis of BPD do not play a role in patients receiving a higher dose of 
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methadone.  The failure to reject the null hypothesis puts the treatment for BPD 
largely on the therapist and client.  The client cannot expect to get complete relief 
from their feelings of distress, emptiness and anxiety by increasing their dosage 
level of methadone beyond what is therapeutically necessary.  This is the crux of 
why it is important to the social work profession in the MMT field.  In the future 
social workers will not be able to only suggest dose increases for MMT patients 
with BPD.  They will have to consider alternative methods of treatment to their 
patients as they seek to help them resolve the sometimes difficult symptomologies 
related to BPD such as psychotherapy and counseling to address distress. 
 Working with clients diagnosed with BPD can be challenging and 
frustrating to social workers.  Social workers in the MMT field must challenge 
their feelings of counter-transference when working with clients who feel dis-
regulated and are seeking higher methadone dosage levels to assuage their 
feelings of distress.  Seeking help from the medical team is one answer to this 
issue.  Having a client who is feeling in distress and seeking a higher methadone 
dose see a nurse or physician for blood work to confirm whether the dose they are 
receiving is at a therapeutic level is one answer to this problem.  Advocating for 
this type of test and the constant work of teaching clients with BPD how to self-
regulate and self-sooth are the major challenges to therapists working with clients 
with BPD and participating in an MMT program. 
METHADONE DOSE AND BORDERLINE PERSONALITY DISORDER 41 
 
 Important for future studies of MMT will be what effect does age play in 
the methadone dosage levels of patients of MMT.  This study found a weak 
correlation between age and methadone dosage levels of MMT patients receiving 
mental health services.  This data could imply that many patients need higher 
doses of methadone as they age.  Also worth consideration are the high mean 
doses given to patients diagnosed with Generalized Anxiety Disorder and 
Dysthymic Disorder.  These are phenomena that would require further research.   
 In the end, mental health therapists, licensed alcohol and drug counselors, 
nurses, physicians and their patients must work together to ensure that each 
patient  is receiving the proper treatment for the mental illness, methadone dose 
and on-going sobriety support as they continue to improve their lives.  This is not 
an easy charge.  Quality communication including case notes, treatment plans and 
case consultation will need to be in place to ensure that the patient’s needs are 
being best served by medical staff, the addiction focused counseling team and the 
mental health counseling staff. 
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Appendix A 
Measurement Instrument 
Gender:  M   F 
Age      _____ 
Methadone Dose   _________________ 
DSM IV-TR Co-Morbid diagnosis     Axis I    _______________________ 
     Axis II_________________________ 
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Appendix B 
 
The confidentiality of all alcohol and drug abuse patient records maintained by this 
program is protected by federal laws and regulations.---------- will not disclose any 
information about any patient, except under the following exceptions: 
 
• Internal program communications 
• Communications that do not disclose the identity of the patient 
• Proper written consent has been provided by the patient 
• Communications during medical emergencies 
• Court-ordered disclosures 
• Communication with law enforcement officials regarding crimes committed by 
patients on clinic premises or against clinic employees 
• Communication in conjunction with research, audit, or evaluation 
• Reporting of suspected child abuse and neglect 
• Qualified service organization agreement (QSOA) 
 
Violations of the federal law and regulations by a program are a crime. Suspected 
violations may be reported either at the program or against any person who works for 
the program or about any threat to commit such a crime. 
 
------------. is required by federal law to provide patient’s with a copy of the policy 
outlined above. A copy of this policy is contained in the patient orientation booklet. 
Signature on this form indicates understanding of the confidentiality provided by you by 
the center. (For details, see 42 CFR, Part 2) 
 
PATIENT’S CONFIDENTIALITY POLICY 
State and federal law protects records and the fact that patients are enrolled in our 
program. Patients will receive further information in this regard on other forms 
throughout the intake process. The purpose of this notice is to inform you of --------- 
expectations for the confidentiality of you and Patients. We expect you to respect the 
confidentiality of patients you know or meet while you are working at this treatment at 
our center. In other words, what you see here and what you hear here in regards to 
patients, must stay here. Do not violate another person’s confidentiality by disclosing 
their information in or out of -----------.  
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________________________________________________         ____________ 
Signature of Client          Date 
   
        
________________________________________________      ______________ 
Signature of Witness                                     Date 
                        
         
 
